Statistics

Total Visits

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial20

File Visits

Downloads
VERSION EDITOR.pdf10

Select a period of time:

Number of views in the range

Views
FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial11

Number of downloads in the range

Downloads
VERSION EDITOR.pdf6

Views

Views
April 20242
May 20241
June 20242
July 20241
August 20240
September 20245
October 20240
Download CSV file
 untranslated
 untranslated

Number of downloads in the period of time

  • Downloads
  • April 2024
    1
  • May 2024
    2
  • June 2024
    2
  • July 2024
    1
  • August 2024
    0
  • September 2024
    0
  • October 2024
    0
  • Download CSV file
 untranslated
 untranslated

Top country views

Views
United States8
Finland2
Spain1
 

Top countries by downloads

Downloads
United States6
 

Top cities views

Views
Helsinki2
Chicago1
Fort Worth1
Santiago de Compostela1
 

Top cities by downloads

Downloads
Fort Worth2